U.S. markets close in 1 minute
  • S&P 500

    4,072.55
    -4.02 (-0.10%)
     
  • Dow 30

    34,434.65
    +39.64 (+0.12%)
     
  • Nasdaq

    11,463.78
    -18.67 (-0.16%)
     
  • Russell 2000

    1,892.57
    +10.89 (+0.58%)
     
  • Crude Oil

    80.11
    -1.11 (-1.37%)
     
  • Gold

    1,811.70
    -3.50 (-0.19%)
     
  • Silver

    23.42
    +0.57 (+2.51%)
     
  • EUR/USD

    1.0536
    +0.0008 (+0.07%)
     
  • 10-Yr Bond

    3.5060
    -0.0230 (-0.65%)
     
  • GBP/USD

    1.2281
    +0.0025 (+0.20%)
     
  • USD/JPY

    134.3390
    -0.9670 (-0.71%)
     
  • BTC-USD

    17,003.54
    +71.06 (+0.42%)
     
  • CMC Crypto 200

    404.06
    +2.63 (+0.66%)
     
  • FTSE 100

    7,556.23
    -2.26 (-0.03%)
     
  • Nikkei 225

    27,777.90
    -448.18 (-1.59%)
     

Innoviva to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

BURLINGAME, Calif., September 08, 2022--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) ("Innoviva"), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14th at 11:10 a.m. Eastern Time.

A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investor Relations section of the Company’s website at https://investor.inva.com/presentations-events, and will be available for replay for 90 days following the event.

About Innoviva

Innoviva is a diversified holding company with a portfolio of royalties and innovative healthcare investments and assets. Its royalty portfolio includes respiratory assets partnered with Glaxo Group Limited ("GSK"), including RELVAR®/BREO® ELLIPTA® (fluticasone furoate/ vilanterol, "FF/VI"), ANORO® ELLIPTA® (umeclidinium bromide/ vilanterol, "UMEC/VI") and, formerly, TRELEGY® ELLIPTA® (the combination FF/UMEC/VI). Under the Long-Acting Beta2 Agonist ("LABA") Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. ANORO®, RELVAR®, BREO®, TRELEGY® and ELLIPTA® are trademarks of the GSK group of companies.

Innoviva strengthened its portfolio in the hospital and infectious disease space through the acquisition of Entasis Therapeutics Holdings Inc. and La Jolla Pharmaceutical Co. Its development pipeline includes potentially first- and best-in-class medicines for the treatment of multidrug-resistant bacteria, including lead asset SUL-DUR. The Company’s commercial and marketed products include GIAPREZA® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA® (eravacycline) for the treatment of complicated intra-abdominal infections (cIAIs).

ANORO®, RELVAR®, BREO®, TRELEGY® and ELLIPTA® are trademarks of the GSK group of companies.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220908005555/en/

Contacts

Investors & Media:
Argot Partners
(212) 600-1902
innoviva@argotpartners.com